I hear and I forget. I see and I remember. I do and I understand. - Confucius

A++ / A--

Vector Asset Management’s goal is to produce financial returns through the quantifiable growth of a business, or the advancement of a technology. Our team of investors, entrepreneurs, and Analyst-Advisors bring decades of experience to help us every step of the way.

We have a history of discreetly identifying high-growth businesses, and discovering disruptive technologies. We force the growth of businesses from start-up to commercial launch and profitability. Along the way, we provide the businesses we support with the requisite business development, marketing, and infrastructure support.

In the case of technology discoveries, we marshal new ideas through development from early inception to advanced prototyping, and eventually through pre-market approvals and full commercial deployment. During the process, we creatively provoke the interest of commercial and industrial partners, and the support of investors through a combination of engineered technology advancements alongside tactical public relations outreach. As a result, our breakthroughs have received coverage in CNN, CNBC, New York Times, The Wall Street Journal, Washington Post, TIME, Forbes, Agence France-Presse (AFP), and others.

In all cases, we build value, generate commercial and financial interest, and produce returns for our investors.



We work proactively with entrepreneurs, inventors, scientists, engineers, and investors seeking breakthrough technologies, and guide the process from initial in-licensing to building the team and implementing the resources required for successful build-out – always within planned budgets and ambitious, achievable timelines.


We have a credible history of operating with government, university, and commercial research laboratories, a relationship which often translates into immediate savings of millions of dollars. Under our guidance one company has entered into several such arrangements; just a single such partnership alone eliminated capital equipment costs to zero while ensuring that highly-talented, professionally qualified, and deeply experienced photovoltaics researchers devoted their energy to the advancement of the technology. Capital which would otherwise have been ‘spent’ on millions of dollars of depreciating research equipment, expensive laboratory space, and cumbersome operating overhead, was otherwise ‘invested’ in pursuit of larger corporate goals.

When targeting new technologies, we identify cost-effective entry points and the genuine prospect of generating exponential returns. For example, our early investment in a medical device company supported its acquisition of an investigative ‘test’ technology for as little as $40,000; we subsequently raised more than $15 million and ultimately leveraged the test technology to acquire a $70 million Phase II-III bioartificial medical device which laid claim the world’s largest-ever human clinical trial of its kind.


Mindful of the state of the capital markets – and at all times working to mitigate the risks associated with building new technologies – we shepherd business build-out and technology development so the company is well-groomed to attract both commercial-industrial partners and financial and strategic investors.

We vigilantly pursue opportunities to acquire ancillary or enabling technologies when they enhance value, attract strategic capital or commercial partnerships, or support industry out-licensing and joint-venture opportunities.


As a technology makes significant strides our team works to creatively stimulate the interest of commercial and industrial partners, and the support of patient investors. We tactically present our advancements through public relations outreach.

We create a compelling product-technology from the ground-up; we generate impactful technical results and share the outcomes with mainstream media. We reach out to our network of long-standing relationships with journalists, writers, bloggers, and authoritative opinion-makers.

Ventures we support have attracted long-term, patient funding and received coverage in CNN, CNBC, MSNBC, CBS, FOX News, New York Times, The Wall Street Journal, Washington Post, TIME, Forbes, Agence France-Presse (AFP), and Reuters, among others.